Navigation Links
Pharmacyclics Announces Promising Results From Phase 2 Clinical,Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung,Cancer

nd the product development of our pipeline; the possibility that the FDA refuses to approve our NDA; because our Phase 3 clinical trial known as the SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial failed to meet its primary endpoint, the FDA may require additional data, analysis or studies before the NDA is approved by the FDA; the outcome of any discussions with the FDA; the initiation, timing, design, enrollment and cost of clinical trials; unexpected delays in clinical trials and preparation of materials for submission to the FDA as part of our NDA filing; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2006 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, Inc., +1-415-225-5050, forPharmacyclics, Inc.

Web site: http://www.pharmacyclics.com/http://www.yourcanceryourchoice.com/

Ticker Symbol: (NASDAQ-NMS:PCYC)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... April 18, 2012  CAQH® announced today that ... the Universal Provider Datasource® (UPD®), demonstrating that ... standard for self-reported provider data used to ... network directories, referrals and claims administration. ...
... Live has revealed further details of the newest event ... (SEA) 2012. Set to debut from 10-12 May 2012 at ... first trade show and exhibition of its kind to be ... CPhI SEA will provide a meeting place ...
Cached Medicine Technology:One Million Healthcare Providers Now Use the CAQH Universal Provider Datasource 2One Million Healthcare Providers Now Use the CAQH Universal Provider Datasource 3Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 2Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 3
(Date:4/24/2014)... A national response to the epidemic of prescription opioid ... England Journal of Medicine by leaders of agencies ... The commentary calls upon health care providers to ... and reduce overdose deaths, and describes a number of ... medications. The commentary also discusses how medications can be ...
(Date:4/24/2014)... NH, 4/24/14) Dartmouth has been awarded one of ... serve as a Lead Academic Participating Site in its ... Award recipients are a select groups of investigators charged ... fewer cooperative groups., The NCTN grant system reflects recommendations ... It streamlines operations to achieve four goals:, ...
(Date:4/24/2014)... scientist at the University of York reveals that a ... of the nervous system may also play a pivotal ... research team, led by Dr Will Brackenbury, a Medical ... York, has studied how voltage-gated sodium channels assist in ... in the membranes of excitable cells, such as neurons, ...
(Date:4/23/2014)... for a new experimental drug to treat acute ... with CPX-351, a combination of the chemotherapeutic drugs ... patients treated with the standard drug formulation. ... aggressive blood cancer with very low rates of ... Lancet, M.D., senior member of the Department of ...
(Date:4/23/2014)... 23, 2014 The American Society for Radiation Oncology ... of Postoperative Radiation Therapy for Endometrial Cancer: An ... adjuvant radiation therapy in the treatment of endometrial ... the May-June 2014 issue of Practical Radiation ... of ASTRO. The full-length guideline is available as ...
Breaking Medicine News(10 mins):Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Breast cancer replicates brain development process 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3
... done too soon can lead to respiratory trouble, other ... -- The rise in Caesarean deliveries could be fueling ... these early births carry risks, including respiratory problems, jaundice ... Tuesday during a March of Dimes conference in New ...
... been selected as the Grand Prize winner of the Jump Start ... ... Hudson, OH (PRWEB) December 18, 2008 -- A resident of ... the Jump Start ,09 national online sweepstakes sponsored by ActiveAmericans.com ...
... wellness center, will implement the C4 IP™ hosted VoIP and ... ... Atlanta, GA (PRWEB) December 18, 2008 -- ... implement the C4 IP™ hosted VoIP and ...
... recognize human gestures could provide a new way for ... related system for the able bodied could also be ... is described in detail in a forthcoming issue of ... , Manolya Kavakli of the Virtual and Interactive Simulations ...
... up after 3 years, study finds , , THURSDAY, Dec. 18 ... medication to prevent narrowing of the artery do better one ... stents, a new study shows. , However, within three years ... a greater risk of more surgery to increase blood flow ...
... Group-based treatment programs may effectively combat childhood obesity ... Florida study. , Children who participated in one of ... less overweight compared with children in a control group. ... Archives of Pediatric and Adolescent Medicine . , The ...
Cached Medicine News:Health News:Elective Early Deliveries Pose Risks for Babies 2Health News:Elective Early Deliveries Pose Risks for Babies 3Health News:Pittsburgh Area Resident Wins $15,000 In Online Sweepstakes 2Health News:MALO CLINIC Avoids Capital Expense and Gains Scalability with Hosted Unified Communications 2Health News:MALO CLINIC Avoids Capital Expense and Gains Scalability with Hosted Unified Communications 3Health News:MALO CLINIC Avoids Capital Expense and Gains Scalability with Hosted Unified Communications 4Health News:Gesture recognition 2Health News:Coated Stents Better Than Bare Metal Ones in Short Run 2Health News:Group treatment may help children achieve healthier weights 2Health News:Group treatment may help children achieve healthier weights 3
... in Canons DR innovations, the CXDI-31 is ... a compact and lightweight design, the Canon ... conventional screen-film cassettes. It is designed to ... to get with fixed devices and supports ...
... a cost-effective synthetic bone filler tailored ... Phosphate (TCP) and Hydroxyapatite (HAP), its ... BAB formulates the chemistry and microstructure ... This formulation provides optimal osteo-conduction. The ...
The Oscor PACE 101 H is an external single chamber cardiac demand pacemaker. The PACE 101 H feature an option for a atrial overdrive stimulation....
... TAU Lead is a ... stimulation lead for temporary ... The unique shaft design ... straight or preformed stylets ...
Medicine Products: